NYSE · RDY
Healthcare · Drug Manufacturers - Specialty & Generic
$11.97
Down-$0.06 (-0.50%)
Updated Sep 8, 2026, 9:50 AM
SID Score
5.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RDY closed at $11.97 after 20 trading sessions, down 1.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $12.01 | $12.06 | $11.905 | $11.97 | 2.34M |
| Sep 3, 2026 | $12.05 | $12.17 | $11.92 | $12.03 | 5.51M |
| Sep 2, 2026 | $12.12 | $12.205 | $12.12 | $12.17 | 4.01M |
| Sep 1, 2026 | $12.21 | $12.28 | $12.15 | $12.17 | 1.93M |
| Aug 31, 2026 | $12.01 | $12.215 | $12.01 | $12.13 | 2.16M |
| Aug 28, 2026 | $12.33 | $12.33 | $12.115 | $12.18 | 1.67M |
| Aug 27, 2026 | $12.18 | $12.235 | $12.13 | $12.16 | 1.55M |
| Aug 26, 2026 | $12.25 | $12.30 | $12.135 | $12.22 | 1.67M |
| Aug 25, 2026 | $12.28 | $12.375 | $12.22 | $12.34 | 1.77M |
| Aug 24, 2026 | $12.24 | $12.25 | $12.13 | $12.22 | 2.07M |
| Aug 21, 2026 | $12.13 | $12.225 | $12.065 | $12.18 | 2.02M |
| Aug 20, 2026 | $12.12 | $12.23 | $12.05 | $12.11 | 2.55M |
| Aug 19, 2026 | $12.17 | $12.215 | $11.99 | $12.11 | 3.26M |
| Aug 18, 2026 | $12.12 | $12.21 | $12.06 | $12.15 | 3.07M |
| Aug 17, 2026 | $12.20 | $12.24 | $12.06 | $12.11 | 2.04M |
| Aug 14, 2026 | $12.33 | $12.385 | $12.215 | $12.27 | 2.26M |
| Aug 13, 2026 | $12.43 | $12.51 | $12.37 | $12.42 | 2.8M |
| Aug 12, 2026 | $12.34 | $12.42 | $12.325 | $12.39 | 2.22M |
| Aug 11, 2026 | $12.55 | $12.58 | $12.415 | $12.45 | 2.37M |
| Aug 10, 2026 | $12.235 | $12.285 | $11.58 | $12.15 | 1.97M |
The latest Smart Investors Daily articles mentioning RDY.
RDY research
Company profile and research snapshot.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 6, 2021 | Sharekhan | Buy | — |
| Jul 28, 2021 | Prabhudas Lilladher | Accumulate | — |
| Jul 28, 2021 | Axis Direct | Buy | — |
| Jul 28, 2021 | ICICI Securities Limited | Hold | — |
| Jul 28, 2021 | Motilal Oswal | Neutral | — |
No generated briefing is available yet.
ChartMill · Feb 27, 2026
DR. Reddy's Laboratories fits Peter Lynch's GARP strategy with strong earnings growth, low debt, and a reasonable PEG ratio, making it a potential long-term compounder.
Yahoo · Feb 20, 2026
HYDERABAD, India, February 20, 2026--Dr. Reddy’s announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.
Benzinga · Feb 20, 2026
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced that the US Food and Drug Administration (USFDA)
Benzinga · Feb 2, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RDY.
